Peer Reviewed

1

Document Type

Article

Publication Date

1-2-2013

Keywords

neuroblastoma, genetics

Comments

The final publication is available at http://link.springer.com

Abstract

Neuroblastoma is a highly heterogeneous tumor accounting for 15 % of all pediatric cancer deaths. Clinical behavior ranges from the spontaneous regression of localized, asymptomatic tumors, as well as metastasized tumors in infants, to rapid progression and resistance to therapy. Genomic amplification of the MYCN oncogene has been used to predict outcome in neuroblastoma for over 30 years, however, recent methodological advances including miRNA and mRNA profiling, comparative genomic hybridization (array-CGH), and whole-genome sequencing have enabled the detailed analysis of the neuroblastoma genome, leading to the identification of new prognostic markers and better patient stratification. In this review, we will describe the main genetic factors responsible for these diverse clinical phenotypes in neuroblastoma, the chronology of their discovery, and the impact on patient prognosis.

Disciplines

Genetics | Medicine and Health Sciences

Citation

Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatric Surgery International. 2013 Feb;29(2):101-19.

PubMed ID

23274701

DOI Link

10.1007/s00383-012-3239-7

Share

COinS